NetworkNewsBreaks – Akero Therapeutics, Inc. (NASDAQ: AKRO) Closes $105.8 Million IPO
Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (“NASH”) and other serious metabolic disorders, has closed its initial public offering, resulting in gross proceeds of approximately $105.8 million. The offering of 6,612,500 shares included 862,500 additional shares per the full exercise of the over-allotment option granted to the underwriters. The shares, sold each at the public offering price of $16.00, began trading on the Nasdaq Global Select Market on June 20, 2019 under the ticker symbol "AKRO." ROTH Capital Partners acted as lead manager for the offering. To view the full press…







